NCT06735326View on ClinicalTrials.gov

Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

November 27, 2024

Primary Completion Date

August 1, 2026

Study Completion Date

October 1, 2028

Conditions
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Interventions
DRUG

Fluzoparib

Fluzoparib capsule (50mg per capsule) 150mg po BID

DRUG

Bevacizumab

Bevacizumab injection (100mg per vial) 7.5mg/kg ivdrip Q3W

DRUG

Paclitaxel

Paclitaxel injection 135-175mg/㎡ ivdrip Q3W

DRUG

Carboplatin

Carboplatin injection AUC=4-5 ivdrip Q3W

Trial Locations (1)

250000

RECRUITING

Qilu Hospital of Shandong University, Jinan

All Listed Sponsors
lead

Qilu Hospital of Shandong University

OTHER